A Single-Cell Analysis Reveals Macrophage Heterogeneity Driving Plaque Vulnerability in Coronary and Carotid Arteries

Takeshi Yoshida1, Takuo Emoto2, Hiroyuki Yamamoto3

  • 1Division of Advanced Medical and Pharmaceutical Sciences, Graduate School of Science, Technology and Innovation, Kobe University.

Insights

Atherosclerosis in coronary and carotid arteries shares a common macrophage inflammatory pathway. However, distinct metabolic profiles in each suggest tailored therapies are needed for plaque vulnerability.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Biology

Background:

  • Atherosclerosis underlies acute coronary syndrome (ACS) and ischemic stroke.
  • Coronary and carotid atherosclerosis exhibit distinct morphological and histological features.
  • Understanding these differences is key for developing targeted therapies.

Purpose of the Study:

  • Compare coronary artery disease (CAD) subtypes (ACS, CCS) with carotid artery disease (CAD) subtypes (symptomatic, asymptomatic).
  • Identify disease-specific mechanisms and therapeutic targets in atherosclerosis.

Main Methods:

  • Single-cell RNA sequencing data from coronary and carotid artery disease datasets were analyzed.
  • Myeloid cells were isolated for comparative metabolic profiling and RNA velocity analysis.
  • Multiple velocity-inference tools (TFvelo, CellRank) were integrated.

Main Results:

  • A shared trajectory toward interleukin-1B (IL1B)+ inflammatory macrophages expressing MMP19 was identified in both coronary and carotid lesions.
  • This pathway involves activation of glycolytic and glycosaminoglycan degradation.
  • Carotid lesions uniquely showed glycolytic activation in SPP1+ foamy macrophages.

Conclusions:

  • Both coronary and carotid atherosclerosis share a common pathway to IL1B+ inflammatory macrophages, indicating shared plaque vulnerability mechanisms.
  • Distinct glycolytic pathway activation in carotid lesions suggests vascular bed-specific therapeutic strategies are required.
  • Targeting macrophage subsets and metabolic pathways may offer tailored treatments for atherosclerosis.
Abstract